US-Listed In Vitro & In Vivo Diagnostic Substances — Net Income Percentiles, FY 2024
Population: 19 US-listed companies (SIC 2835), fiscal year 2024; fiscal year ends 2024-12-29 to 2025-05-31.
Cite as: FACTANKER, https://factanker.com/industries/sic-2835/net-income/2024
Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest
| 10th percentile | $-633.6M |
|---|---|
| 25th percentile | $-83.4M |
| Median | $-23.4M |
| 75th percentile | $-723.4k |
| 90th percentile | $64.4M |
| Mean | $-153.1M |
| Minimum | $-2.1B |
| Maximum | $887.9M |
Methodology & sources
Net Income as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2024 = fiscal years ending 2024-06-01 to 2025-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-07.
Net Income as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2024 = fiscal years ending 2024-06-01 to 2025-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-07.
Evidence samples
Latest Net Income percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries